BACKGROUND AROUND COPD AND THE ASSOCIATED MORBIDITY AND MORTALITY
Chronic obstructive pulmonary disease (COPD) is a major non-communicable disease, associated with substantial morbidity and mortality [1] . There is a general agreement that an estimated number of 328 million people have COPD worldwide, of which 168 million are men and 160 million are women [2] .
It is likely that in 2020, of 68 million deaths worldwide, 4.3 million will be caused by COPD [3] , although there was a downward trend in COPD mortality at least in Europe between 1994 and 2010 [4] . However, the World Health Organization estimates that by 2030, COPD will become globally the third-leading cause of death also because almost 90% of COPD deaths will occur in low-and middle-income countries [5] .
COPD has a major effect on healthcare costs, particularly direct medical costs. Thus, appropriate long-term interventions are recommended to lower the economic burden of COPD [6] . Although the economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities [7] , the three most important factors in individual patients that determine the economic and societal costs of COPD are always disease severity, presence of frequent exacerbations of disease and the presence of comorbidities, which are common (30-57%) in COPD patients [8] .
Consequently, drug treatment of COPD is mainly aimed at reducing symptoms, frequency and severity of exacerbations, and in improving quality of life, lung function and exercise tolerance [9, 10] . In general, the presence of comorbidities should not alter COPD treatment and comorbidities should be treated as if the patient did not have COPD [9] .
In all current guidelines and recommendations of the management of COPD, inhaled bronchodilators are the pillar of therapy at each stage of the disease [9] [10] [11] . A recent systematic review with meta-analysis has suggested that dual bronchodilation with long-acting muscarinic antagonist (LAMA)/long-acting b 2 -agonist (LABA) is always more effective than the LAMA or LABA alone in terms of the improvement in trough FEV 1 [12] . Furthermore, LAMA/ LABA fixed dose combinations (FDCs) also improve both transitional dyspnea index (TDI) and St. George's Respiratory Questionnaire (SGRQ) scores, and do not increase the cardiovascular risk when compared with monocomponents. Several LABA/LAMA FDCs have been developed or are in clinical development [13] . Indacaterol/glycopyrronium (QVA149) has been the first LABA/LAMA FDC to be developed and approved as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD [12, 14] . In this article we review the evidence that supports use of this FDC in the treatment of COPD. The review is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. [30] . Unexpectedly, the gradient of effectiveness calculated using available results of clinical trials suggests that indacaterol/glycopyrronium 27.5/15.6 lg twice-daily is slightly better than indacaterol/glycopyrronium 110/50 lg once-daily with the change in trough FEV 1 being the primary outcome [12] .
MECHANISM OF ACTION, DOSE AND ADMINISTRATION OF THE INDACATEROL/ GLYCOPYRRONIUM COMBINATION

THE ROLE OF LAMA/LABA AND DUAL BRONCHODILATION IN TREATMENT STRATEGIES
Since there is no solid guidance on when to combine two bronchodilators with different mechanisms of action, an answer to the question ''whether and when a second bronchodilator can or must be added in patients with stable COPD'' is imperative [13] .
The 2017 updated version of Global Initiative for Chronic Obstructive Lung Disease (GOLD)
report stated that combinations of a LABA and a LAMA significantly increase lung function and in studies where patient reported outcomes (PROs) are the primary endpoint or in pooled analyses, combination bronchodilators have a greater impact on PROs compared to monotherapies [9] . As already mentioned, a systematic review with meta-analysis that incorporated the data from trials lasting at least 3 months to evaluate the effectiveness of LAMA/LABA FDCs for COPD treatment documented that dual bronchodilation is always more effective than the LAMA or LABA alone in terms of the improvement in trough FEV 1 , TDI, and SGRQ scores compared with monocomponents [12] . Although the mean difference between LAMA/LABA FDCs and monocomponents for TDI score is usually 0.5
and that for SGRQ score is 2, both statistically significant but lower than the MCID thresholds, the associated reductions in reliever medication use suggest clinical relevance [31] .
Accordingly, we advocate the need to start immediately, until the time of diagnosis, the treatment of COPD patients with LABA/LAMA FDC in order to optimize bronchodilation using the full doses currently approved for the treatment of COPD, although we strongly believe that the synergistic interaction between LABAs and LAMAs supports the possibility of an intervention with low doses of LABA/LAMA combination to optimise bronchodilation and reduce the risk of adverse events that characterise both LABAs and LAMAs, especially when administered at the full doses currently approved for the treatment of COPD [32] .
LAMA/LABA IN THE PREVENTION OF EXACERBATIONS
There is a general agreement that, given the high prevalence of COPD, the impact of exacerbations on quality of life and the costs incurred, effective ways for the prevention of exacerbations and for reductions in the severity and duration of COPD symptoms are needed [33] .
A post hoc analysis of the ILLUMINATE trial, a multicentre double-blind, double-dummy, parallel-group study that enrolled COPD patients without exacerbations in the previous year, although 19 [38] , and consequently reducing the risk of acute exacerbations of COPD. We believe that also the reduced release of non-neuronal acetylcholine from the epithelium but not from bronchi caused by the co-administration of indacaterol and glycopyrronium is extremely important to explain the potential ability of dual bronchodilation in preventing acute exacerbations of COPD [37] . Actually, it is well known that non-neuronal acetylcholine plays an important inflammatory role [39] . In any case, the reduction in the release of non-neuronal acetylcholine from the epithelium is also important in generating the relevant synergistic interaction between glycopyrronium and indacaterol in small airways where the density of vagal innervation is insignificant or even absent [40] , thus suggesting a role of the non-neuronal cholinergic system in regulating bronchial tone.
Regrettably, all these studies do not allow determining the real value of preventing COPD exacerbations when patients are treated according to the reported severity of All these studies were conducted before approval of the LABA/LAMA FDCs that are now available for the treatment of COPD but the use of LABA ? LAMA free combinations was minimal. This is not really surprising considering that, according to the British National Institute for Health and Care
Excellence guidelines [45] , not yet updated, treatment with LAMAs plus LABAs is recommended in people with COPD who remain symptomatic on treatment with a LABA alone, whereas the LABA/LAMA combination is not recommended in those already taking a LAMA as sole maintenance therapy. Actually, there is documentation from a retrospective study, which used real-life data, that tiotropium is associated with significantly better disease outcomes in all measures investigated when compared to salbutamol/ ipratropium [46] . Unfortunately, there is no data yet available on the benefit of LABA/LAMA FDC over LAMA, and also LABA, in real life although the results of pivotal randomized clinical trials indicate that this is the case.
Pending these data, it is important to decide whether it makes sense to switch all patients from a LABA/ICS regimen to a LABA/LAMA regimen on the basis of the improvement in lung function and the lower exacerbation rates.
A recent meta-analysis of randomized clinical trials of at least 12 weeks of duration comparing LABA/LAMA and LABA/ICS combinations has shown that LABA/LAMA was associated with greater improvement in FEV 1 than LABA/ICS, but both treatments appeared clinically equivalent in improving SGRQ, TDI, and CAT scores [47] . Due to the recognized limitation of [48] . Conversely, it might be of help in patients with suboptimal adherence to treatment, since perceived rapid efficacy could reinforce compliance. It could also be useful in patients with more variable symptoms [49] . We strongly believe the rapid improvement in symptoms could help patients' adherence to treatment, which may be otherwise discouraged by a ''slow'' gradual therapeutic strategy as suggested by guidelines and recommendations [50] . However, also the relative simplicity and convenience of once-daily dosing (compared with multiple daily dosing) may encourage patients' adherence and persistence with their long-term medications [48] . It is clear that at this stage we need a long-term study in real life to confirm that the fast onset and sustained duration of effect are critical to ensure adherence to treatment by patients who are under regular treatment with indacaterol/ glycopyrronium FDC. We must also determine whether this LABA/LAMA FDC impacts better than a once-daily LABA/ICS FDC on PROs.
Since the treatment of COPD must be maintained over time, it is important to highlight that the overall superiority of LABA/ LAMA FDCs is greater after 3 months of treatment, while it slightly diminished after 6 and 12 months of treatment [51] . This trend suggests that continued improvements in FEV 1 elicited by LABA/LAMA combinations can be expected over the first 3 months of treatment; after that, the greater benefits of dual bronchodilation remains stable. Thus, it seems that for long-acting bronchodilator agents the time taken to reach the clinical bronchorelaxant steady state is considerably longer than the time taken to achieve the pharmacodynamic steady state, meaning that the LABA/LAMA interaction is fundamental, not only after acute administration, but also over time in the course of chronic treatment [51] .
Choosing the optimum therapy for our patients with COPD is becoming increasingly difficult. From the perspective of a third-party payer, the optimum combination may be one that carries the lowest immediate cost, or that has the most favourable cost/risk ratio [52] . Lowering co-pays for maintenance drugs could result in improved adherence and, ultimately, decreased overall health-care spending [53] . Data generated using a patient-level simulation model in which Monte Carlo simulation methods were used to follow individual patients over various time horizons in a Swedish healthcare setting have shown that indacaterol/glycopyrronium FDC is cost-saving when compared with the free combination of indacaterol ? glycopyrronium and cost-effective when compared with salmeterol/fluticasone FDC, in patients with moderate or severe COPD and low exacerbation risk [54] .
Another study that assessed the cost effectiveness of the dual bronchodilator indacaterol/glycopyrronium compared with salmeterol/fluticasone combination in patients with moderate-to-severe COPD who had a history of one or no exacerbations in the previous year, used a patient-level simulation that was developed to compare the costs and outcomes of the two combinations based on data from the LANTERN trial [55] . Indacaterol/ glycopyrronium was found to be the dominant (more effective and less costly) treatment option compared with SFC in Canada, France, Italy, and Portugal. The use of indacaterol/ glycopyrronium was associated with mean total cost savings per patient over a lifetime of €6202, €1974, €1611, and €220 in Canada, France, Italy, and Portugal, respectively. Sensitivity analysis showed that exacerbation rates had the largest impact on incremental costs and quality-adjusted life-years (QALYs). The probability of indacaterol/glycopyrronium being cost effective was estimated to be [95% for thresholds above €5000/QALY.
INDACATEROL/ GLYCOPYRRONIUM: CHOOSING THE RIGHT DEVICE
While the choice of drug used for treatment is reasonably easy for the majority of COPD patients, the choice of delivery device is less clear, particularly in view of the ever growing, and at times confusing, number and types of devices that contain the same chemical entity [56] . The ideal device to be used by a COPD patient has a universal design, is independent of patient inspiratory force and can deliver a consistent and reproducible dose into the lungs with patient compliance [57] .
Indacaterol/glycopyrronium is delivered via the Breezhaler dry powder inhaler (DPI). DPIs do not need coordination of inhalation with activation and do not require hand strength. However, in the elderly the ability to generate adequate inspiratory flows through DPIs is compromised. The majority of patients with COPD are advanced at the time of diagnosis.
They are middle-aged or older and some of the more severely affected patients are elderly.
Nevertheless, the Breezhaler device is a low-resistance (specific airflow resistance of 2.2 9 10 -2 kPa l -1 min) capsule-based DPI.
The Breezhaler requires less inspiratory effort than other DPIs to achieve a given inspiratory flow or, as reflected in the inspiratory flow profiles, permits a higher inspiratory flow for a given effort [58] . Consequently, it is suitable for use by patients with a wide range of COPD severities, delivering a consistent dose irrespective of disease severity and age [59] .
In a cross-sectional study that use the COPD who may benefit the most from this therapy [37] .
A possible answer to this question will come in a future that we hope will not be too far when treatable traits will be used simultaneously with the assessment of endotype and/or disease activity biomarkers [31] . The identification of a distinct biologic COPD exacerbation phenotype (e.g., bacteria predominant vs eosinophilic predominant phenotype) could help to prescribe more effective targeting of preventive treatments (i.e., LABA/LAMA combination ± macrolides vs ICS-containing regimen), although this may prove difficult, because exacerbation mechanisms can change from one exacerbation to the next [31] . 
